Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Linical CoTSE:2183 +0.49%40 Equity-to-Asset is 0.33 as of Mar. 2026, which is 21% below its 10-year median of 0.42. GuruFocus rates TSE:2183 with a GF Score™ of 40/100 and a GF Value™ of 円338.85 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 1,412 Biotechnology companies, Linical Co ranks worse than 78.05% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Linical Co's Total Stockholders Equity for the quarter that ended in Mar. 2026 was 円3,976 Mil. Linical Co's Total Assets for the quarter that ended in Mar. 2026 was 円12,000 Mil.
Therefore, Linical Co's Equity to Asset Ratio for the quarter that ended in Mar. 2026 was 0.33.
The historical rank and industry rank for Linical Co's Equity-to-Asset or its related term are showing as below:
TSE:2183'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.33 Med: 0.42 Max: 0.56
Current: 0.33
During the past 13 years, the highest Equity to Asset Ratio of Linical Co was 0.56. The lowest was 0.33. And the median was 0.42.
TSE:2183's Equity-to-Asset is ranked worse than 78.05% of 1412
companies
in the Biotechnology industry
Industry Median: 0.69
vs TSE:2183: 0.33
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Linical Co Equity-to-Asset Related Terms
Linical Co Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Linical Co's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:2183 vs VRTX, REGN, MRNA: Equity-to-Asset Comparison
For the Biotechnology subindustry, Linical Co's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Linical Co Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Linical Co's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Linical Co's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Linical Co's Equity to Asset Ratio for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Linical Co (TSE:2183) has a Equity-to-Asset of 0.33 as of Mar. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Linical Co and its competitors. This is 21% below median its historical median of 0.42. Over the past decade, Linical Co's Equity-to-Asset has ranged from 0.33 to 0.56. According to the industry distribution chart, Linical Co ranks #1102 out of 1412 companies in the Biotechnology industry, placing it in the top 78%.
Is Linical Co's Equity-to-Asset too high?
Linical Co's current Equity-to-Asset of 0.33 is 21% below median its 10-year median of 0.42. Over the past 10 years, this metric has ranged from a low of 0.33 to a high of 0.56. The Biotechnology industry median Equity-to-Asset is 0.69. Linical Co's value of 0.33 is 52.2% below this industry median. Based on the distribution chart, Linical Co ranks #1102 out of 1412 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Linical Co has a GF Score™ of 40/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Linical Co's Equity-to-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Linical Co ranks #1102 out of 1412 companies for Equity-to-Asset. This places Linical Co in the lower half of its industry. The industry median Equity-to-Asset is 0.69. Linical Co's value of 0.33 is 52.2% below this benchmark. Historically, Linical Co's own Equity-to-Asset has ranged from 0.33 to 0.56 over the past decade. While the company's 10-year median is 0.42 vs. the industry median of 0.69, Linical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.69, based on 1,412 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Linical Co's current Equity-to-Asset of 0.33 is 52.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Linical Co and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Linical Co's current Equity-to-Asset is 0.33, which is 21% below median its own 10-year median of 0.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Linical Co stock overvalued right now?
Based on GuruFocus' analysis, Linical Co (TSE:2183) is currently considered Possible Value Trap. The stock's GF Value™ is 円338.85, compared to a current price of 円204.00 — trading 39.8% below its estimated fair value. The current Equity-to-Asset is 0.33, which is 21% below median its 10-year median of 0.42 and 52.2% below the Biotechnology industry median of 0.69. Linical Co's overall GF Score™ is 40/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Linical Co (TSE:2183), the current Equity-to-Asset is 0.33 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Linical Co (TSE:2183) Overvalued in 2026?
Based on GuruFocus' analysis, Linical Co stock appears to be undervalued.
The current stock price of 円204.00 is trading 39.8% below its estimated GF Value™ of 円338.85.
GuruFocus considers Linical Co to be Possible Value Trap.
Key valuation signals for TSE:2183:
Equity-to-Asset: 0.33 (21% below median its 10-year median of 0.42)
GF Value™: 円338.85 vs. price of 円204.00 (39.8% below fair value)
Industry Position: 52.2% below the Biotechnology median (#1102 of 1412)
No single metric tells the full story. See the TSE:2183 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:2183 has been successfully added to your 
